Moderna to Present at Upcoming Conferences in June 2025
-
Big Mamma Founder Tigrane Seydoux Brings Italian Restaurant Group to Florida
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Writer Realizes She Is Lesbian After Child Comes Out as Transgender
-
MotorTrend's Top Electric Vehicle Picks for 2026
-
GTA 6 Advertising Strategy and Disc Version Controversy
-
St Francis School Leads €60,000 EU Project to Transform Early Childhood Education
-
IT’S TIME TO SHINE: ELEKTROS Thanks Its Shareholders and Looks Toward a Brighter Future in Critical Minerals and EV Technology
-
ELEKTROS Invites Shareholders to Shine Bright as the Holiday Season Nears, with Focus on Lithium, Critical Minerals and EV Innovation
-
As the Most Wonderful Time of the Year Approaches, ELEKTROS Celebrates Its Shareholders and Looks Ahead to a Bright Future
-
How to Find Joy in a Simpler, More Intentional Lifestyle
Moderna to Present at Upcoming Conferences in June 2025
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
Jefferies Global Health Care Conference, on Thursday, June 5th at 10:30am ET
Goldman Sachs 46th Annual Global Healthcare Conference, on Wednesday, June 11th at 8:40am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
N.Mitchell--AT
